Citations

Showing 10 of 108094 citations.

P1094: CHARACTERISTICS, MANAGEMENT, AND OUTCOMES OF PATIENTS WITH T-CELL LARGE GRANULAR LYMPHOCYTIC LEUKEMIA AT A LARGE TERTIARY CARE CENTER
Audil, Hadiyah Y. , Hampel, Paul J. , Call, Tim G., Hanson, C., Wang, Y., Koehler, Amber B. , Schwager, Susan M., Leis, José F., Kenderian, Saad J., Al‐Kali, Aref , Nowakowski, Grzegorz S. , Shah, M., Rabe, Kari G. , Ding, Wei , Bennani, N. Nora , Call, Timothy G., Wang, Yucai , Slager, Susan L. , Shi, Min , Parikh, Sameer A.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 984-985

10.1097/01.hs9.0000847244.78761.0a Get It

P1100: BRUIN MCL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR CHOICE OF BTK INHIBITOR IN PATIENTS WITH PREVIOUSLY TREATED, BTK INHIBITOR NAÏVE MCL (TRIAL IN PROGRESS)
Eyre, Toby A. , Shah, N. N., Dreyling, Martin, Wang, Y., Gandhi, M., Chay, C., Sharman, Jeff P. , Andorsky, David , Yin, Ming , Balbas, Minna, Kherani, Jennifer , Wang, M. L., Gouill, Steven Le , Vandenberghe, Elisabeth , Jurczak, Wojciech , Wang, Yucai , Cheah, Chan Y. , Yin, M.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 990-991

10.1097/01.hs9.0000847268.67095.fc Get It

P1041: IMPACT OF FEDRATINIB ON SPLEEN VOLUME AND MYELOFIBROSIS SYMPTOMS IN PATIENTS WITH SUBSTANTIAL SPLENOMEGALY: POST HOC ANALYSES FROM THE JAKARTA AND JAKARTA2 TRIALS
Kiladjian, J.‐J., Tefferi, Ayalew , Vannucchi, A. M., Cervantes, F. , Harrison, Claire , Rose, S., Zhang, J., Sy, Oumar, Pardanani, Animesh , Passamonti, Francesco , Vannucchi, Alessandro M , Talpaz, Moshe , Mesa, Ruben A. , Mascarenhas, John , Schaap, Nicolaas , Verstovšek, Srđan , Devos, Timothy

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 931-932

10.1097/01.hs9.0000847032.10304.60 Get It

Alzheimer's disease cerebrospinal fluid biomarkers differentiate patients with Creutzfeldt–Jakob disease and autoimmune encephalitis
Chang, Bryce Kalei , Day, Gregory S. , Graff‐Radford, Jonathan, Nguyen, Aivi T. , Toledano, Michel , Kremers, Walter K. , Petersen, Ronald C. , Chang, Bryce K , Day, Gregory S , Nguyen, Aivi T , Kremers, Walter K , Graff‐Radford, Jonathan , McKeon, Andrew , Flanagan, Eoin P. , Algeciras‐Schimnich, Alicia , Mielke, Michelle M. , Jones, David T. , Knopman, David S. , Li, Wentao

Mayo Clinic

European Journal of Neurology | June 23, 2022 | Volume: 29 | Issue: 10 | Pages: 2905-2912

10.1111/ene.15469 | PMID 35735602 Get It

AbstractBackground and purposeAutoimmune encephalitis (AE) is a potentially treatable cause of rapidly progressive dementia that may mimic Creutzfeldt–Jakob disease (CJD). Alzheimer disease (AD) cerebrospinal fluid (CSF) biomarkers may discriminate CJD from AD, but utility in discriminating CJD and AE is unclear. This study compared AD CSF biomarkers in CJD and AE.MethodsPatients with probable or definite CJD and probable or definite AE who underwent Roche Elecsys AD CSF biomarker testing at Mayo Clinic from March 2020 through April 2021 were included. Total‐tau, phosphorylated181 tau and amyloid‐β42 levels were compared.ResultsOf 11 CJD cases, four were autopsy proven; the rest had positive real‐time quaking‐induced conversion testing. Disease‐associated autoantibodies were detected in 8/15 cases of AE: leucine‐rich glioma‐inactivated 1 and neuronal intermediate filaments (two cases each), and N‐methyl‐d‐aspartate receptor, contactin‐associated protein‐like 2, dipeptidyl‐peptidase‐like protein 6 and immunoglobulin‐like cell adhesion molecule IgLON family member 5. Total‐tau provided excellent discrimination between CJD and AE in a univariate model (odds ratio 1.46 per 100 pg/ml, 95% confidence interval 1.17–2.11, p < 0.05, c = 0.93). Total‐tau was elevated in 91% of CJD cases (median > 1300, range 236–>1300 pg/ml), of which 55% were above the limit of assay measurement (>1300 pg/ml). Total‐tau was elevated in 20% of AE cases (median 158, range 80–>1300 pg/ml).ConclusionTotal‐tau was greater in CJD than AE. Given that amyloid‐β42 and phosphorylated181 tau were comparable, the ratio differences were probably driven by elevated total‐tau in CJD. This study supports the role for AD biomarker testing in patients with rapidly progressive dementia.
P730: GENETIC LANDSCAPE OF SOMATIC MYELOID MUTATIONS IN THE PRESENCE OF RARE TERT VARIANTS AND THEIR RELATION WITH MYELOID NEOPLASIA
Mangaonkar, A., Lasho, T., Wylam, Mark E. , Finke, C., Fernández, José Parejo, He, Rong , Viswanatha, David S., Patnaik, M., Ferrer, Alejandro , Lasho, Terra L. , Finke, Christy M. , Fernandez, J.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 625-626

10.1097/01.hs9.0000845804.52338.42 Get It

P787: SABATOLIMAB (MBG453) COMBINATION TREATMENT REGIMENS FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES: THE MYELODYSPLASTIC SYNDROMES STUDIES IN THE STIMULUS IMMUNO-MYELOID CLINICAL TRIAL PROGRAM
Al‐Kali, Aref , Borate, Uma , Cluzeau, Thomas , DeZern, A. E., Kobata, Kazuma, Lyons, Roger M. , Sallman, David A. , Xiao, Zhijian , Hoef, Marlies Van, Nourry-Boulot, Claire, Sadek, Islam Mohamad, IORDAN, Ana-Maria, Sabo, Jennifer L., Garcia‐Manero, G., Zeidan, Amer M. , Esteve, Jordi , Giagounidis, Aristoteles , Platzbecker, Uwe , Santini, Valeria , Sanz, Guillermo , Sekeres, Mikkael A. , Wei, Andrew H. , Ma, Fei

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 682-683

10.1097/01.hs9.0000846032.37876.c9 Get It

P642: IMPACT OF TYPE 2 DIABETES ON SURVIVAL AND TREATMENT IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Andersen, Michael Asger , Vainer, Noomi , Hjalgrim, Henrik , Frederiksen, Henrik , Frederiksen, Henrik , Rotbain, Emelie Curovic , Rostgaard, Klaus , Cunha‐Bang, Caspar da , Slager, Susan L. , Niemann, Carsten Utoft

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 540-541

10.1097/01.hs9.0000845452.89743.80 Get It

P682: NEMTABRUTINIB (MK-1026), A NON-COVALENT INHIBITOR OF WILD-TYPE AND C481S MUTATED BRUTON TYROSINE KINASE FOR B-CELL MALIGNANCIES: EFFICACY AND SAFETY OF THE PHASE 2 DOSE-EXPANSION BELLWAVE-001 STUDY
Woyach, Jennifer A. , Eradat, Herbert, Brander, Danielle M. , Tees, Michael, Wang, W., Reddy, Nishitha , Farooqui, Mohammed, Flinn, Ian W. , Awan, Farrukh T. , Parikh, Sameer A. , Phillips, Tycel , Byrd, John C. , Stephens, Deborah M.

Mayo Clinic

HemaSphere | June 23, 2022 | Volume: 6 | Issue: No issue available | Pages: 578-579

10.1097/01.hs9.0000845612.25766.0c Get It